Abstract:Purpose of review: The goals of this review are two folds: (1) to describe the recent understandings on the roles of calcitonin gene-related peptide-α (CGRP) in bone homeostasis and the underlying mechanisms of related neuronal regulation and (2) to propose innovative CGRP-modulated approaches for enhancing bone regeneration in challenging bone disorders. Recent findings: CGRP is predominantly produced by the densely distributed sensory neuronal fibers in bone, declining with age. Under mechanical and biochemical stimulations, CGRP releases and exerts either physiological or pathophysiological roles. CGRP at physiological level orchestrates the communications of bone cells with cells of other lineages, affecting not only osteogenesis, osteoclastogenesis, and adipogenesis but also angiogenesis, demonstrating with pronounced anabolic effect, thus is essential for maintaining bone homeostasis, with tuned nerve-vessel-bone network. In addition, its effects on immunity and cell recruitment are also crucial for bone fracture healing. Binding to the G protein-coupled receptor composited by calcitonin receptor-like receptor (CRLR) and receptor activity modifying protein 1 (RAMP1) on cellular surface, CGRP triggers various intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and cAMP response element-binding protein (CREB). Peaking at early stage post-fracture, CGRP promotes bone formation, displaying with larger callus. Then CGRP gradually decreases over time, allowing normal or physiological bone remodeling. By elevating CGRP at early stage, low-intensity pulsed ultrasound (LIPUS), electrical stimulation, and magnesium-based bio-mineral products may promisingly accelerate bone regeneration experimentally in medical conditions like osteoporosis, osteoporotic fracture, and spine fusion. Excess CGRP expression is commonly observed in pathological conditions including cancer metastatic lesions in bone and fracture delayed- or non-healing, resulting in persistent chronic pain. To date, these discoveries have largely been limited to animal models. Clinical applications are highly desirable. Compelling evidence show the anabolic effects of CGRP on bone in animals. However, further validation on the role of CGRP and the underlying mechanisms in human skeletons is required. It remains unclear if it is type H vessel connecting neuronal CGRP to osteogenesis, and if there is only specific rather than all osteoprogenitors responsible to CGRP. Clear priority should be put to eliminate these knowledge gaps by integrating with high-resolution 3D imaging of transparent bulk bone and single-cell RNA-sequencing. Last but not the least, given that small molecule antagonists such as BIBN4096BS can block the beneficial effects of CGRP on bone, concerns on the potential side effects of humanized CGRP-neutralizing antibodies when systemically administrated to treat migraine in clinics are arising.

Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

Abstract 449: Growth Hormone-releasing Hormone Agonist Attenuates Vascular Calcification and Vascular Injury in Diabetic Db/db Mice

Ghrelin Blunted Vascular Calcification in Vivo and in Vitro in Rats.

Ghrelin Attenuates The Osteoblastic Differentiation Of Vascular Smooth Muscle Cells Through The Erk Pathway

Knockdown of Estrogen‐related Receptor Α Inhibits Valve Interstitial Cell Calcification in Vitro by Regulating Heme Oxygenase 1

GDF10 is a negative regulator of vascular calcification

Hedgehog signaling is a potential therapeutic target for vascular calcification

Abstract 723: Agonist of Growth Hormone Releasing Hormone Enhances Angiogenic Therapy by Mesenchymal Stem Cells

The Protective Effect of GLP-1 Analogue in Arterial Calcification Through Attenuating Osteoblastic Differentiation of Human VSMCs

Cortistatin attenuates vascular calcification in rats

Effects of GHRH and Its Analogues on the Vascular System

Effects of adrenomedullin, C-type natriuretic peptide, and parathyroid hormone-related peptide on calcification in cultured rat vascular smooth muscle cells

Shh–Gli2–Runx2 inhibits vascular calcification

Angiotensin-(1-7) Inhibits Vascular Calcification in Rats

Abstract 3145: Inactivating the Adenosine 2A Receptor Reduces Vascular Calcification Through Modulating Osteogenic Differentiation of Vascular Cells

Hyaluronan negatively regulates vascular calcification involving BMP2 signaling

Adrenomedullin up-regulates osteopontin and attenuates vascular calcification via the cAMP/PKA signaling pathway

The Effects of Calcitonin Gene-Related Peptide on Bone Homeostasis and Regeneration

Targeting Androgen Receptor in Macrophages Inhibits Phosphate-Induced Vascular Smooth Muscle Cell Calcification by Decreasing IL-6 Expression

κ-opioid receptor stimulation alleviates rat vascular smooth muscle cell calcification via PFKFB3-lactate signaling